Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ludwig Boltzmann Institut for Health Technology Assessment. Bevacizumab (AvastinĀ®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal cancer. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). Horizon Scanning in Oncology No. 46
. 2014 Indexing Status Subject indexing assigned by CRD MeSH Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Humans Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32014001408 Date bibliographic record published 26/11/2014 Date abstract record published 28/11/2014 |